# US 2021/0277023 A1 · Antibiotic conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277023 A1
- Document ID: US20210277023A1
- Status: Published application
- Kind: A1
- Application number: 17/054,054
- Filed: 2018-08-09
- Published: 2021-09-09
- Earliest claimed: 2018-05-09
- Assignees: University of Notre Dame du Lac
- Applicants: University of Notre Dame Du Lac
- Inventors: Marvin J. MILLER; Rui LIU; Patricia MILLER; Sergei VAKULENKO; Nichole K. STEWART; William BOGGESS
- Web page: https://patentgrep.com/patent/US20210277023A1

## CPC

- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/431: containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 47/547: {Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}
- A61K 47/552: {one of the codrug's components being an antibiotic}
- A61P 31/04: Antibacterial agents
- C07D 501/16: with a double bond between positions 2 and 3
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided are antibiotic conjugate compounds of formula (I) and pharmaceutical compositions thereof. Also provided are methods of treating treat bacterial infection, including infections caused by Gram-negative bacteria, by administering compounds of formula (I).

## Claims

### Claim 1

A compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein
Sid is a siderophore moiety;
L is a bond or a linker moiety;
G is -G1 or —X—(CH2)pC(O)-G1;
X is O or S;
p is 0, 1, 2, 3, 4, or 5; and
G1 is a drug moiety attached through an oxygen or nitrogen atom.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
L is bond, —C(O)—, —C(O)NHCH(R1)—C(O)—, —C(O)OCH(R2)—C(O)—, or
R1 and R2 are each hydrogen, C1-6alkyl, cyano, C3-6cycloalkyl, C3-6cycloalkenyl, 6- to 12-membered aryl, or 5- to 12-membered heteroaryl, wherein the cycloalkyl, cycloalkenyl, aryl, or heteroaryl is optionally substituted with 1-5 substituents independently selected from the group consisting of halogen, C1-4alkyl, C1-4haloalkyl, —O1-4alkyl, —OC1-4haloalkyl, OH, oxo, and cyano;
R3 and R4 are each independently hydrogen, C1-6alkyl, or R3 and R4 together with the C atom to which they are attached form a 3- to 8-membered ring;
Cyc1 is a 6- to 12-membered aryl or 5- to 12-membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1-5 substituents independently selected from the group consisting of halogen, C1-4alkyl, C1-4haloalkyl, —OC1-4alkyl, —OC1-4haloalkyl, OH, oxo, and cyano; and
Y is O or NH.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is bond, —C(O)—, or —C(O)NHCH(R1)—C(O)—.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is —C(O)NHCH(R1)—C(O)—.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is phenyl.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Sid is selected from the group consisting of
wherein Ra and Rb are each independently hydrogen or C1-4 alkyl,

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are each independently hydrogen, C1-6alkyl.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 and R4 together with the C atom to which they are attached form a 3- to 8-membered ring.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 and R4 together with the C atom to which they are attached form
wherein t is 0, 1, 2, 3, 4, or 5.

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cyc1 is

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Y is NH

### Claim 13 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Sid is selected from the group consisting of

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G is G1.

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G is —OC(O)-G1.

### Claim 16 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
L is bond, —C(O)—, or —C(O)NHCH(R1)—C(O)—,
R1 is phenyl; and
G is G1 or —OC(O)-G1.

### Claim 17 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G1 is selected from the group consisting of amikacin, aminoglycoside, amoxicillin, amphotericin, ampicillin, ansamycin, azithromycin, aztreonam, bacillomycin, biapenem, carbacephalosporins, carbapenem, carbomycin, carbomycin A, carumonam, cefaclor, cefalotin, cephalosporin, cethromycin, chloramphenicol, chlortetracycline, ciprofloxacin, clarithromycin, clindamycin, cycloserine, daptomycin, demeclocycline, dirithromycin, doripenem, doxorubicin, doxycycline, ertapeneme, erythromycin, ethambutol, fluoroquinolone, gentamicin, isoniazid, josamycin, kanamycin, kitasamycin, lincomycin, linezolid, loracarbef, macrolide, meropenem, methacycline, midecamycin, monobactams, monocarbams, mupirocin, neomycin, nystatin, oleandomycin, oleandomycin, oxazolidinones, oxytetracycline, panipenem, penem, penicillin, peptide antibiotic, polymixin, pyrrolnitrin, quinolone, rhamoplanin, rifampin, rifamycins, rolitetracycline, roxithromycin, solithromycin, spiramycin, streptomycin, sulfabenzamide, sulfacetamide, sulfadiazine, sulfadoxine, sulfamerazine, sulfamethazine, sulfamethizole, sulfamethoxazole, sulfisoxazole, sulfonamide, teichoplanin, telithromycin, tetracycline, tigimonam, troleandomycin, tylosin, tylocine, and vancomycin.

### Claim 18 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G1 is oxazolidinone.

### Claim 19 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein formula (I) is formula (A),
wherein n is 0 or 1; and m is 0 or 1.

### Claim 20 (depends on 1)

The compound of claim 1, having a structure of
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

A method of treating bacterial infection, comprising administering to a subject infected by a bacterium an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the bacterium is a Gram-positive bacterium or a Gram-negative bacterium.

### Claim 23 (depends on 21)

The method of claim 21, wherein the bacterium is a Gram-negative bacterium.

### Claim 24 (depends on 21)

The method of claim 21, wherein the bacterium is an antibiotic-resistant bacterium.

### Claim 25 (depends on 21)

The method of claim 21, wherein the bacterium produces a β-lactamase.

### Claim 26 (depends on 21)

The method of claim 21, wherein the infection is caused by Acinetobacter, Pseudomonas, Enterobacteria, or combinations thereof.

### Claim 27 (depends on 21)

The method of claim 21, wherein the infection is caused by Acinetobacter baumannii.

### Claim 28 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 29 (depends on 1)

A method of killing or inhibiting the growth of a bacterium, comprising contacting the bacterium with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the bacterium is a Gram-positive bacterium or a Gram-negative bacterium.

### Claim 31 (depends on 29)

The method of claim 29, wherein the bacterium is a Gram-negative bacterium.

### Claim 32 (depends on 29)

The method of claim 29, wherein the bacterium is an antibiotic-resistant bacterium.

### Claim 33 (depends on 29)

The method of claim 29, wherein the bacterium produces a β-lactamase.

### Claim 34 (depends on 29)

The method of claim 29, wherein the infection is caused by Acinetobacter, Pseudomonas, Enterobacteria, or combinations thereof.

### Claim 35 (depends on 29)

The method of claim 29, wherein the infection is caused by Acinetobacter baumannii.
